Analyst Viewpoint
Surge in prevalence of Alzheimer’s among geriatric population and growth in investments in healthcare facilities are fueling the dementia associated with Alzheimer’s disease market size. Dementia progresses over time among the aging population, and Alzheimer’s and Parkinson’s being its major cause require proper treatments and therapies. Growth in geriatric population across the globe is driving the prevalence of Alzheimer’s and Parkinson’s diseases, thereby fostering market expansion.
Increase in adoption of gene therapy and biomarkers is likely to offer lucrative dementia associated with Alzheimer’s disease market opportunities to leading market players. They are focusing on innovative drug development and conducting clinical trials to seek drug approvals. These strategies are expected to enable drug manufacturers to enhance their product portfolio and improve business performance by providing precise dementia treatments.
Alzheimer's disease is the most common type of dementia. Dementia is a progressive disease beginning with mild memory loss and possibly leading to loss of control of memory, language, and thought. Lack of functioning of brain proteins, called neurons, is one of the major causes of Alzheimer’s-related dementia. Neurodegenerative disorders caused by Alzheimer’s and Parkinson’s disease are a major concern among the population.
Neuropathological changes in the cerebral cortex and limbic system lead to deficit in learning, memory, language, and visuospatial skills, leading to Alzheimer's-induced cognitive impairment. Loss of spontaneity, taking longer to complete daily tasks, losing track of dates and locations, and forgetting or repeating questions are some of the common symptoms of dementia. Dementia associated with Alzheimer's disease can be treated using memantine, an N-Methyl-D-Aspartate (NMDA) antagonist.
Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects geriatric population and the prevalence of dementia tends to increase with age. Vascular dementia, Lewy body dementia, and frontotemporal dementia are caused due to Alzheimer’s. Growth in geriatric population across the globe is leading to an increase in prevalence of dementia associated with Alzheimer's disease. This, in turn, is driving dementia associated with Alzheimer’s disease industry growth.
According to the World Health Organization, in 2020, the number of people aged 60 years and older outnumbered children younger than 5 years. Between 2015 and 2050, the proportion of the world's population over 60 years is expected to nearly double from 12% to 22%.
Developments in healthcare facilities across the globe are fueling the availability of treatments and therapies for these diseases. Emerging therapies for Alzheimer's-related dementia treatment are likely to boost lucrative dementia associated with Alzheimer’s disease market dynamics in the near future. For instance, in September 2022, the WHO stated that about 55 million people worldwide are living with dementia, and nearly 10 million cases are reported annually. WHO also stated that Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia.
Healthcare professionals focus on reducing the risk associated with drugs for Alzheimer’s disease by adopting advanced precision medicine. These medicines include biomarkers and gene therapy for the treatment of dementia associated with Alzheimer’s disease. Emergence of digital therapeutics and artificial intelligence in Alzheimer's research are major market trends in diagnostic tools for Alzheimer's-associated dementia. An increase in use of biomarkers and imaging techniques for the diagnosis and management of Alzheimer's disease enables physicians to provide efficient and precise treatments. Thus, surge in investments in healthcare facilities is bolstering lucrative dementia associated with Alzheimer’s disease market statistics.
Technological advancements in the drug development sector enable manufacturers to introduce innovative medicine according to disease severity and causes. Advancements in neuroscience research and development of novel therapeutic approaches are boosting market progress. Drug development organizations are conducting multiple clinical trials to record impact and side-effects of the drugs. Hence, introduction of new therapies and treatments is likely to offer lucrative dementia associated with Alzheimer’s disease business opportunities in the next few years.
As per the latest dementia associated with Alzheimer’s disease industry analysis, North America dominated the global market in 2022. Rise in aging population and availability of advanced medical facilities are some of the crucial factors projected to propel dementia associated with Alzheimer’s disease market share during the forecast period. Moreover, surge in prevalence of dementia and increase in investments in research and development of dementia therapies are boosting market revenue in the region.
According to the Journal of the Alzheimer’s Association, in the U.S., around 1 in 9 people, which comprises 10.7% of the people aged 65 and older, have dementia due to Alzheimer’s. Approximately 5.0% of the population aged 65 to 74, 13.1% of the population aged 75 to 84, and 33.2% of the population aged 85 and older, have Alzheimer’s dementia.
Leading players in the lucrative dementia associated with Alzheimer’s disease market are investing heavily in drug development by conducting in-depth research on the causes, symptoms, and severity of the diseases. They are focusing on providing precise and advanced treatments to ensure efficient results and cater to consumer demands. Prominent players are launching new products and conducting clinical trials to seek approvals from government organizations, thereby enhancing their product portfolio.
Some of the key players in the industry are Merz Pharma, Novartis AG, AbbVie Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd.
These companies have been profiled in the dementia associated with Alzheimer’s disease market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 6.2 Bn |
| Market Forecast (Value) in 2031 | US$ 9.3 Bn |
| Growth Rate (CAGR) | 4.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Tons | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 6.2 Bn in 2022
It is projected to register a CAGR of 4.6% from 2023 to 2031
Rise in prevalence of Alzheimer's among geriatric population and growth in investments in healthcare facilities
North America was the most lucrative region in 2022
Merz Pharma, Novartis AG, AbbVie Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dementia Associated with Alzheimer’s Disease Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecasts, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Cholinergic/Cholinesterase (ChE) Inhibitors
6.3.2. Memantine
6.3.3. Combined Drugs (Memantine & Donepezil)
6.3.4. Others
6.4. Market Attractiveness, by Drug Class
7. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail
7.3.3. Online Sales
7.4. Market Attractiveness, by Distribution Channel
8. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017–2031
9.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
9.2.2. Memantine
9.2.3. Combined Drugs (Memantine & Donepezil)
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail
9.3.3. Online Sales
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
10.2.2. Memantine
10.2.3. Combined Drugs (Memantine & Donepezil)
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail
10.3.3. Online Sales
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
11.2.2. Memantine
11.2.3. Combined Drugs (Memantine & Donepezil)
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail
11.3.3. Online Sales
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
12.2.2. Memantine
12.2.3. Combined Drugs (Memantine & Donepezil)
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail
12.3.3. Online Sales
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
13.2.2. Memantine
13.2.3. Combined Drugs (Memantine & Donepezil)
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail
13.3.3. Online Sales
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Merz Pharma
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. AbbVie Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Pfizer, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Daiichi Sankyo Company, Limited.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Ono Pharmaceutical Co., Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Johnson & Johnson Services, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Eisai Co., Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. H. Lundbeck A/S
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. F. Hoffmann-La Roche Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
List of Tables
Table 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 2: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 3: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 4: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 5: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 6: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 7: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 8: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 9: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 10: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 12: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 16: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 18: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
List of Figures
Figure 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 2: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Drug Class, 2022
Figure 3: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Distribution Channel, 2022
Figure 4: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 5: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 6: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 7: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 8: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Region, 2022 and 2031
Figure 9: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Region, 2023–2031
Figure 10: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country, 2022 and 2031
Figure 12: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country, 2023–2031
Figure 13: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 14: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 15: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 16: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 17: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 18: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 19: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 20: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 21: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 22: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 23: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 24: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 27: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 28: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 29: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 30: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 31: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 32: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 34: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 35: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 36: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 37: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 39: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 40: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 41: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 42: Global Dementia Associated with Alzheimer’s Disease Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Dementia Associated with Alzheimer's Disease Market
*86 figures and 60 tables includes